NovaBay Pharmaceuticals, Inc. (NBY)
USD 0.49
(-0.45%)
USD 0.49
(-0.45%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -5 Million USD | 34.86% |
| 2022 | -7.68 Million USD | 13.34% |
| 2021 | -8.86 Million USD | -37.91% |
| 2020 | -6.42 Million USD | 31.64% |
| 2019 | -9.4 Million USD | -19.43% |
| 2018 | -7.87 Million USD | -7.66% |
| 2017 | -7.31 Million USD | 33.43% |
| 2016 | -10.98 Million USD | 47.74% |
| 2015 | -21.01 Million USD | -24.51% |
| 2014 | -16.87 Million USD | -8.99% |
| 2013 | -15.48 Million USD | -86.38% |
| 2012 | -8.3 Million USD | -92.29% |
| 2011 | -4.32 Million USD | 4.32% |
| 2010 | -4.51 Million USD | -264.82% |
| 2009 | 2.74 Million USD | 132.2% |
| 2008 | -8.5 Million USD | -44.81% |
| 2007 | -5.87 Million USD | -6.33% |
| 2006 | -5.52 Million USD | -54.83% |
| 2005 | -3.56 Million USD | -27.28% |
| 2004 | -2.8 Million USD | -194.23% |
| 2003 | -953 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -1.57 Million USD | -96.87% |
| 2024 Q2 | -1.05 Million USD | 32.97% |
| 2023 Q1 | -1.73 Million USD | -163.52% |
| 2023 FY | -5 Million USD | 34.86% |
| 2023 Q2 | -1.35 Million USD | 21.86% |
| 2023 Q3 | -1.11 Million USD | 17.64% |
| 2023 Q4 | -798 Thousand USD | 28.49% |
| 2022 Q4 | 2.73 Million USD | 697.37% |
| 2022 Q1 | -2.38 Million USD | 25.42% |
| 2022 FY | -7.68 Million USD | 13.34% |
| 2022 Q2 | -2.15 Million USD | 9.66% |
| 2022 Q3 | -457 Thousand USD | 78.76% |
| 2021 Q4 | -3.19 Million USD | -39.54% |
| 2021 FY | -8.86 Million USD | -37.91% |
| 2021 Q1 | -1.52 Million USD | 13.54% |
| 2021 Q2 | -1.85 Million USD | -22.3% |
| 2021 Q3 | -2.28 Million USD | -23.13% |
| 2020 Q4 | -1.75 Million USD | 14.74% |
| 2020 Q1 | -1.53 Million USD | 31.41% |
| 2020 Q2 | -1.07 Million USD | 30.23% |
| 2020 FY | -6.42 Million USD | 31.64% |
| 2020 Q3 | -2.06 Million USD | -92.53% |
| 2019 Q2 | -1.37 Million USD | 66.13% |
| 2019 Q4 | -2.23 Million USD | -30.72% |
| 2019 FY | -9.4 Million USD | -19.43% |
| 2019 Q1 | -4.07 Million USD | -152.7% |
| 2019 Q3 | -1.71 Million USD | -24.15% |
| 2018 Q2 | -2.08 Million USD | 12.04% |
| 2018 FY | -7.87 Million USD | -7.66% |
| 2018 Q3 | -1.8 Million USD | 13.15% |
| 2018 Q4 | -1.61 Million USD | 10.95% |
| 2018 Q1 | -2.36 Million USD | -704.08% |
| 2017 Q3 | -2.16 Million USD | -23.45% |
| 2017 Q2 | -1.75 Million USD | 53.48% |
| 2017 Q1 | -3.77 Million USD | -76.5% |
| 2017 FY | -7.31 Million USD | 33.43% |
| 2017 Q4 | 392 Thousand USD | 118.07% |
| 2016 Q1 | -4.62 Million USD | 24.76% |
| 2016 Q4 | -2.14 Million USD | -6.31% |
| 2016 FY | -10.98 Million USD | 47.74% |
| 2016 Q3 | -2.01 Million USD | 8.71% |
| 2016 Q2 | -2.2 Million USD | 52.31% |
| 2015 Q2 | -4.85 Million USD | -4.25% |
| 2015 Q4 | -6.14 Million USD | -14.92% |
| 2015 Q3 | -5.34 Million USD | -10.06% |
| 2015 FY | -21.01 Million USD | -24.51% |
| 2015 Q1 | -4.66 Million USD | 4.9% |
| 2014 Q4 | -4.9 Million USD | -19.16% |
| 2014 Q1 | -4.07 Million USD | 16.19% |
| 2014 FY | -16.87 Million USD | -8.99% |
| 2014 Q2 | -3.78 Million USD | 7.16% |
| 2014 Q3 | -4.11 Million USD | -8.64% |
| 2013 Q4 | -4.86 Million USD | -63.18% |
| 2013 Q2 | -4.15 Million USD | -19.01% |
| 2013 Q3 | -2.98 Million USD | 28.14% |
| 2013 FY | -15.48 Million USD | -86.38% |
| 2013 Q1 | -3.48 Million USD | -22.7% |
| 2012 Q4 | -2.84 Million USD | -2581.13% |
| 2012 FY | -8.3 Million USD | -92.29% |
| 2012 Q1 | -2.48 Million USD | -0.69% |
| 2012 Q2 | -2.87 Million USD | -15.69% |
| 2012 Q3 | -106 Thousand USD | 96.31% |
| 2011 Q4 | -2.46 Million USD | -609.2% |
| 2011 Q2 | 440 Thousand USD | 122.62% |
| 2011 Q1 | -1.94 Million USD | -3141.67% |
| 2011 FY | -4.32 Million USD | 4.32% |
| 2011 Q3 | -348 Thousand USD | -179.09% |
| 2010 Q3 | -1.64 Million USD | -38.09% |
| 2010 Q4 | -60 Thousand USD | 96.35% |
| 2010 Q2 | -1.19 Million USD | 26.33% |
| 2010 Q1 | -1.61 Million USD | -147.1% |
| 2010 FY | -4.51 Million USD | -264.82% |
| 2009 Q3 | -89 Thousand USD | 67.99% |
| 2009 Q2 | -278 Thousand USD | 15.5% |
| 2009 Q1 | -329 Thousand USD | 79.42% |
| 2009 FY | 2.74 Million USD | 132.2% |
| 2009 Q4 | 3.43 Million USD | 3959.55% |
| 2008 Q1 | -2.83 Million USD | -81.64% |
| 2008 Q4 | -1.59 Million USD | -2.11% |
| 2008 Q3 | -1.56 Million USD | 37.46% |
| 2008 FY | -8.5 Million USD | -44.81% |
| 2008 Q2 | -2.5 Million USD | 11.8% |
| 2007 Q2 | -1.67 Million USD | -64.53% |
| 2007 Q1 | -1.01 Million USD | 82.3% |
| 2007 Q3 | -1.62 Million USD | 2.51% |
| 2007 Q4 | -1.56 Million USD | 3.99% |
| 2007 FY | -5.87 Million USD | -6.33% |
| 2006 Q3 | 208 Thousand USD | 113.93% |
| 2006 FY | -5.52 Million USD | -54.83% |
| 2006 Q2 | -1.49 Million USD | -22.58% |
| 2006 Q1 | -1.21 Million USD | -40.65% |
| 2006 Q4 | -5.73 Million USD | -2856.73% |
| 2005 Q4 | -866 Thousand USD | 0.0% |
| 2005 Q2 | -866 Thousand USD | 0.0% |
| 2005 FY | -3.56 Million USD | -27.28% |
| 2005 Q3 | -866 Thousand USD | 0.0% |
| 2005 Q1 | -866 Thousand USD | 0.0% |
| 2004 FY | -2.8 Million USD | -194.23% |
| 2003 FY | -953 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -31.91 Million USD | 84.324% |
| Ampio Pharmaceuticals, Inc. | -9.51 Million USD | 47.436% |
| Armata Pharmaceuticals, Inc. | -40.89 Million USD | 87.765% |
| Actinium Pharmaceuticals, Inc. | -51.92 Million USD | 90.364% |
| Azitra, Inc. | -7.61 Million USD | 34.313% |
| Can-Fite BioPharma Ltd. | -8.19 Million USD | 38.951% |
| Chromocell Therapeutics Corporation | -6.86 Million USD | 27.094% |
| Calidi Biotherapeutics, Inc. | -28.99 Million USD | 82.744% |
| CEL-SCI Corporation | -31.47 Million USD | 84.105% |
| iBio, Inc. | -16.63 Million USD | 69.923% |
| Lineage Cell Therapeutics, Inc. | -24.73 Million USD | 79.772% |
| MAIA Biotechnology, Inc. | -20.18 Million USD | 75.211% |
| Matinas BioPharma Holdings, Inc. | -23.76 Million USD | 78.949% |
| Navidea Biopharmaceuticals, Inc. | -14.05 Million USD | 64.394% |
| NanoViricides, Inc. | -8.51 Million USD | 41.253% |
| Oragenics, Inc. | -20.9 Million USD | 76.068% |
| BiomX Inc. | -27.68 Million USD | 81.929% |
| BiomX Inc. | -27.68 Million USD | 81.929% |
| Protalix BioTherapeutics, Inc. | 10.46 Million USD | 147.83% |
| Palatin Technologies, Inc. | -22.49 Million USD | 77.761% |
| Scorpius Holdings, Inc. | -42.03 Million USD | 88.097% |
| Theriva Biologics, Inc. | -21.43 Million USD | 76.655% |